Migraine

The prescription remote electrical neuromodulation device is now cleared for both acute and preventive treatment of migraine in those aged ≥12 years, according to Theranica.

Pain relief from the intranasally-delivered calcitonin gene-related peptide antagonist began as soon as 15 minutes post-dose and for some patients lasted up to 48 hours.

Your daily dose of clinical news you may have missed.

Study participants with medication overuse headache reported quality of life improvements as early as study week 4 that were sustained at week 24.

Among women with prepregnancy migraine diagnosis, rates of gestational hypertension and preeclampsia were 28% and 40% higher, respectively, vs women without migraine.

The Nerivio REM device demonstrated a statistically significant reduction in migraine days/month vs a placebo device in both chronic and episodic migraine.

Adults with migraine with aura were found at significantly greater risk for AF and those younger than age 55 years were particularly vulnerable, write Mayo Clinic investigators.

If the atogepant label is expanded, the drug will be the only gepant approved for the broad indication of prevention of both episodic and chronic migraine.

Yale headache specialist Christopher Gottschalk, MD, talks about the opportunities to make a marked difference in the quality of patients' lives.

The CGRP inhibitor class of injectable migraine preventive agents has a very favorable side effect profile but the drugs do come with some cautions, says Christopher Gottschalk, MD.

Opioid refills were reduced by ~40% in the 9 months following an initial prescription for rimegepant among patients with migraine, a new study found.

The migraine-specific oral gepants are proving effective across the continuum of migraine frequency. Dr Gottschalk talks about their shaky start.

"Primary Viewpoints," a podcast from Patient Care Online, brings you an exclusive interview with headache specialist Peter McAllister, MD.

Gottschalk says CGRP inhibitors have made "...a life-changing transformation in how we think about and the kind of expectations we set for migraine treatment."

Christopher Gottschalk, MD, a leader in migraine research and clinical care, talks about what drew him to headache medicine early on and what it used to be like.

Individuals with migraine were found more likely to have IBS and IBS was more prevalent in those with migraine; both associations were statistically significant.

Findings for atogepant from the phase 3 PROGRESS study will form the basis of a submission by AbbVie to FDA for a label expansion in the US.

Consider migraine screening for all women aged 20 to 50 years, suggests Ailani; you'll likely find a majority of them have migraine. More pearls follow.

Migraine-specific preventive therapies should be in the primary care toolbox, according to headache specialist Jessica Ailani, MD.

Migraine headache specialist and researcher Jessica Ailani, MD, fully supports primary care as the setting for the majority of the treatment for the disease.

Lifetime use of opioids for migraine was found to be higher than for triptan medications. Try these 10 questions on other OVERCOME findings.

Findings on use of acute and preventive migraine therapy continue to reveal gaps with far more patients eligible than the proportions using either type.

Researchers identified over 120 regions connected to risk of migraine, of which 86 were previously unknown.

Researchers also found that women with migraine with aura had a higher risk of preeclampsia than those with migraine without aura.

Intranasal CGRP inhibitor zavegepant met coprimary regulatory endpoints in pivotal phase 3 trial in adults with migraine; FDA submission planned for Q1 2022.